Sydney Stewart, Author at BioTuesdays

Markets

Brookline boosts life sciences equity research

Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team. With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...

June 24, 2020

Markets

HCW starts Aprea Therapeutics at neutral; PT $30

H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...

June 22, 2020

Developments

Soliton posts positive pivotal cellulite trial results

Soliton (NASDAQ:SOLY) presented new positive data from the company’s pivotal cellulite clinical trial at the American Academy of Dermatology 2020 virtual conference. The trial enrolled and treated 67 subjects at four...

June 15, 2020

Developments

NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints

A Phase 2 trial supported by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) concluded that BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal influenza vaccine candidate achieved safety and...

June 10, 2020

Markets

Maxim resumes coverage of Moleculin Biotech at buy; PT $3

Maxim Group resumed coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.11 on June 5. On May 1, the SEC suspended trading in Moleculin, citing questions about the...

June 8, 2020

Developments

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...

June 1, 2020

Developments

Repare Therapeutics in research collaboration with Bristol Myers

Closely-held Repare Therapeutics inked an exclusive, worldwide research collaboration with Bristol Myers Squibb (NYSE:BMY). Under the accord, the companies will leverage Repare’s CRISPR-enabled genome-wide synthetic...

May 28, 2020

Markets

HCW ups CymaBay Therapeutics to buy; PT $9

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral,” with a price target of $9, citing a possible lifting of the clinical hold on seladelpar development in liver disease. The stock closed...

May 26, 2020

Markets

Raymond James adds Profound Medical to “analyst current favorite”

Raymond James added Profound Medical (TSX:PRN; NASDAQ:PROF) as an “analyst current favorite,” maintaining a “strong buy” recommendation, after AstraZeneca and Merck received FDA approval for their PARP inhibitor drug...

May 22, 2020

Developments

Bee Vectoring in cranberry trials with natural pesticide

Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) plans to conduct trials of its natural precision agriculture system on cranberries in Massachusetts and New Jersey, two major cranberry growing...

May 20, 2020

Author - Sydney Stewart

Brookline boosts life sciences equity research

HCW starts Aprea Therapeutics at neutral; PT $30

Soliton posts positive pivotal cellulite trial results

NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints

Maxim resumes coverage of Moleculin Biotech at buy; PT $3

Ocugen to discontinue Phase 3 oGVHD trial

Repare Therapeutics in research collaboration with Bristol Myers

HCW ups CymaBay Therapeutics to buy; PT $9

Raymond James adds Profound Medical to “analyst current favorite”

Bee Vectoring in cranberry trials with natural pesticide

Subscribe